M1 microglia

By Targets:	Biochemical Assay Reagents (1) CXCR (1) Endogenous Metabolite (1) Environmental Pollutants (1) Interleukin Related (1) Keap1-Nrf2 (1) Liposome (4) Mixed Lineage Kinase (1) MMP (1) NF-κB (2) NOD-like Receptor (NLR) (1) Orphan GPCR (1) Pyroptosis (1) Quinone Reductase (1) RIP kinase (1) SOD (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Inflammation/Immunology (5) Neurological Disease (10)
Oligonucleotides:	Cholesterol (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0131

Stigmasterol 10+ Cited Publications	MMP Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Stigmasterol is an orally acitve, immunomodulatory agent with anti-inflammatory and neuroprotective effect, as well as able to cross the blood-brain barrier. Stigmasterol activates AMPK, which in turn inhibits NF-κB and NLRP3 signaling pathways, reduces microglia-mediated neuroinflammation, and alleviates cognitive impairment and Alzheimer's disease. Stigmasterol regulates M1/M2 polarization of microglia through the TLR4/ NF-κB pathway, thereby reducing neuropathic pain. Stigmasterol can be used for neurodegenerative diseases, inflammatory diseases, and pain management, among others .

HY-156815

YL-365	Orphan GPCR	Neurological Disease Inflammation/Immunology
YL-365 is a potent and selective GPR34 antagonist with an IC₅₀ of 17 nM. YL-365 binds to a portion of the orthosteric binding pocket of GPR34 and induces allosteric changes that stabilize the receptor in an inactive conformation. YL-365 down-regulates expression of the proinflammatory gene iNOS in M1 microglia and suppresses proinflammatory responses. YL-365 reduces mechanical allodynia in a dose-dependent manner in a mouse model of neuropathic pain. YL-365 can be used for the research of neuropathic pain .

HY-N2909

Aurantiamide	NF-κB RIP kinase Mixed Lineage Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-P4111

Peptide R	CXCR	Inflammation/Immunology Cancer
Peptide R is a cyclic peptide and a specific CXCR4 antagonist. Peptide R exhibits excellent ability to effectively remodel tumor stroma. Peptide R has potential for use in tumor research .

HY-P11315

MG1 peptide	Biochemical Assay Reagents	Cardiovascular Disease Neurological Disease
MG1 peptide is an M1 microglia-targeting peptide with blood-brain barrier permeability. MG1 peptide can be used in studies related to ischemic stroke and cerebral ischemia-reperfusion injury .

HY-N2439

Methyl isoeugenol	Environmental Pollutants Pyroptosis SOD Quinone Reductase Keap1-Nrf2 NF-κB	Cardiovascular Disease
Methyl isoeugenol is an orally active, blood-brain barrier-permeable isoeugenol-type eugenol analog. Methyl isoeugenol promotes the nuclear translocation of Nrf2, upregulates the expressions of HO-1, NQO1 and SOD, and reduces the expression level of MDA. Methyl isoeugenol decreases the nuclear translocation of NF-κB. Methyl isoeugenol inhibits NLRP3 inflammasome-mediated pyroptosis. Methyl isoeugenol reduces cerebral infarction volume and regulates the M1/M2 phenotypic balance of microglia. Methyl isoeugenol can be used for the research of cerebral ischemia-reperfusion injury .

HY-155762

Anti-neuroinflammation agent 1	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease Inflammation/Immunology
Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype .

HY-182096C

DSPE-PEG5000-MG1	Liposome	Neurological Disease
DSPE-PEG5000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG5000-KTP can be used for drug delivery .

HY-182096A

DSPE-PEG2000-MG1	Liposome	Neurological Disease
DSPE-PEG2000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG2000-KTP can be used for drug delivery .

HY-182096B

DSPE-PEG3400-MG1	Liposome	Neurological Disease
DSPE-PEG3400-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG3400-KTP can be used for drug delivery .

HY-182096

DSPE-PEG1000-MG1	Liposome	Neurological Disease
DSPE-PEG1000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG1000-KTP can be used for drug delivery .

HY-155949

Bt354		Neurological Disease Cancer
Bt354 is an orally active STAT3 inhibitor with IC₅₀ values of 4.6 μM (DU145), 6.5 μM (MDA-MB-435) and 7.2 μM (MDA-MB-231), respectively. Bt354 induces cell cycle arrest and apoptosis, and downregulates epithelial-mesenchymal transition-related genes. Bt354 exhibits anti-angiogenic and anti-inflammatory activities, attenuates the polarization of M1 microglia and A1 astrocytes, suppresses inflammasome-related signaling pathways, and alleviates mechanical hyperalgesia and thermal hyperalgesia. Bt354 can be used in research related to glioblastoma multiforme, triple-negative breast cancer, prostate cancer and neuropathic pain .

Cat. No.	Product Name	Type

HY-182096C

DSPE-PEG5000-MG1	Biochemical Assay Reagents
DSPE-PEG5000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG5000-KTP can be used for drug delivery .

HY-182096A

DSPE-PEG2000-MG1	Biochemical Assay Reagents
DSPE-PEG2000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG2000-KTP can be used for drug delivery .

HY-182096B

DSPE-PEG3400-MG1	Biochemical Assay Reagents
DSPE-PEG3400-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG3400-KTP can be used for drug delivery .

HY-182096

DSPE-PEG1000-MG1	Biochemical Assay Reagents
DSPE-PEG1000-MG1 is a PEG compound which composed of DSPE and a MG1 peptide (HY-P11315). MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. DSPE-PEG1000-KTP can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P4111

Peptide R	CXCR	Inflammation/Immunology Cancer
Peptide R is a cyclic peptide and a specific CXCR4 antagonist. Peptide R exhibits excellent ability to effectively remodel tumor stroma. Peptide R has potential for use in tumor research .

HY-P11315

MG1 peptide	Biochemical Assay Reagents	Cardiovascular Disease Neurological Disease
MG1 peptide is an M1 microglia-targeting peptide with blood-brain barrier permeability. MG1 peptide can be used in studies related to ischemic stroke and cerebral ischemia-reperfusion injury .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0131

Stigmasterol 10+ Cited Publications	Microorganisms Classification of Application Fields Amaranthaceae Plants Endogenous metabolite Achyranthes bidentata Inflammation/Immunology Disease Research Fields Steroids Source Classification	MMP Endogenous Metabolite
Stigmasterol is an orally acitve, immunomodulatory agent with anti-inflammatory and neuroprotective effect, as well as able to cross the blood-brain barrier. Stigmasterol activates AMPK, which in turn inhibits NF-κB and NLRP3 signaling pathways, reduces microglia-mediated neuroinflammation, and alleviates cognitive impairment and Alzheimer's disease. Stigmasterol regulates M1/M2 polarization of microglia through the TLR4/ NF-κB pathway, thereby reducing neuropathic pain. Stigmasterol can be used for neurodegenerative diseases, inflammatory diseases, and pain management, among others .

HY-N2909

Aurantiamide	Alkaloids Classification of Application Fields Other Alkaloids Umbelliferae Plants Inflammation/Immunology Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray Source Classification	NF-κB RIP kinase Mixed Lineage Kinase
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-N2439

Methyl isoeugenol	Natural Products other families Neurological Disease Classification of Application Fields Plants Pteris semipinnata L. Sp. Disease Research Fields Source Classification	Environmental Pollutants Pyroptosis SOD Quinone Reductase Keap1-Nrf2 NF-κB
Methyl isoeugenol is an orally active, blood-brain barrier-permeable isoeugenol-type eugenol analog. Methyl isoeugenol promotes the nuclear translocation of Nrf2, upregulates the expressions of HO-1, NQO1 and SOD, and reduces the expression level of MDA. Methyl isoeugenol decreases the nuclear translocation of NF-κB. Methyl isoeugenol inhibits NLRP3 inflammasome-mediated pyroptosis. Methyl isoeugenol reduces cerebral infarction volume and regulates the M1/M2 phenotypic balance of microglia. Methyl isoeugenol can be used for the research of cerebral ischemia-reperfusion injury .

Cat. No.	Product Name		Classification

HY-N0131

Stigmasterol 10+ Cited Publications		Cholesterol
Stigmasterol is an orally acitve, immunomodulatory agent with anti-inflammatory and neuroprotective effect, as well as able to cross the blood-brain barrier. Stigmasterol activates AMPK, which in turn inhibits NF-κB and NLRP3 signaling pathways, reduces microglia-mediated neuroinflammation, and alleviates cognitive impairment and Alzheimer's disease. Stigmasterol regulates M1/M2 polarization of microglia through the TLR4/ NF-κB pathway, thereby reducing neuropathic pain. Stigmasterol can be used for neurodegenerative diseases, inflammatory diseases, and pain management, among others .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Oligonucleotides

Name
Email *

	Sorry, but the email address you supplied was invalid.

M1 microglia

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Oligonucleotides

Natural
Products